Literature DB >> 1764384

Growth factors in ovarian cancer.

O J Owens1, C Stewart, R E Leake.   

Abstract

Epidermal growth factor and transforming growth factor alpha are two peptides which bind to the epidermal growth factor receptor. One hundred and seventy-four samples from 133 patients with ovarian cancer were examined for EGF and TGF alpha. EGF was detected in only 27.6% of samples while TGF alpha was present in 88.5%. The median values for TGF alpha presence were at least 10-fold greater than those of EGF. There was no statistical difference between either TGF alpha or EGF levels and degree of differentiation of the tumours. There was no statistical difference between stage three and four in relation to concentration of either peptide. Median concentration did not differ significantly among the histological sub-groups.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1764384      PMCID: PMC1977857          DOI: 10.1038/bjc.1991.486

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  13 in total

1.  Revised FIGO staging for gynaecological cancer.

Authors:  J H Shepherd
Journal:  Br J Obstet Gynaecol       Date:  1989-08

2.  The contribution of the C-terminal undecapeptide sequence of urogastrone-epidermal growth factor to its biological action.

Authors:  H Gregory; C E Thomas; J A Young; I R Willshire; A Garner
Journal:  Regul Pept       Date:  1988-08

Review 3.  Autocrine growth factors and cancer.

Authors:  M B Sporn; A B Roberts
Journal:  Nature       Date:  1985 Feb 28-Mar 6       Impact factor: 49.962

4.  Characterization of growth factors in human ovarian carcinomas.

Authors:  T Bauknecht; M Kiechle; G Bauer; J W Siebers
Journal:  Cancer Res       Date:  1986-05       Impact factor: 12.701

5.  Human platelet-derived growth factor stimulates amino acid transport and protein synthesis by human diploid fibroblasts in plasma-free media.

Authors:  A J Owen; R P Geyer; H N Antoniades
Journal:  Proc Natl Acad Sci U S A       Date:  1982-05       Impact factor: 11.205

6.  Urinary TGFs1 in neoplasia: immunoreactive TGF-alpha in the urine of patients with disseminated breast carcinoma.

Authors:  K Stromberg; W R Hudgins; D N Orth
Journal:  Biochem Biophys Res Commun       Date:  1987-04-29       Impact factor: 3.575

7.  Determination of transforming growth factor activity in effusions from cancer patients.

Authors:  A R Hanauske; C L Arteaga; G M Clark; J Buchok; M Marshall; P Hazarika; R L Pardue; D D Von Hoff
Journal:  Cancer       Date:  1988-05-01       Impact factor: 6.860

8.  Immunoreactive alpha transforming growth factor activity in effusions from cancer patients as a marker of tumor burden and patient prognosis.

Authors:  C L Arteaga; A R Hanauske; G M Clark; C K Osborne; P Hazarika; R L Pardue; F Tio; D D Von Hoff
Journal:  Cancer Res       Date:  1988-09-01       Impact factor: 12.701

9.  The expression of EGF receptors, EGF-like factors and c-myc in ovarian and cervical carcinomas and their potential clinical significance.

Authors:  M Kohler; I Janz; H O Wintzer; E Wagner; T Bauknecht
Journal:  Anticancer Res       Date:  1989 Nov-Dec       Impact factor: 2.480

10.  Distinct high-performance liquid chromatography pattern of transforming growth factor activity in urine of cancer patients as compared with that of normal individuals.

Authors:  E S Kimball; W H Bohn; K D Cockley; T C Warren; S A Sherwin
Journal:  Cancer Res       Date:  1984-08       Impact factor: 12.701

View more
  2 in total

1.  The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer.

Authors:  J M Bartlett; S P Langdon; B J Simpson; M Stewart; D Katsaros; P Sismondi; S Love; W N Scott; A R Williams; A M Lessells; K G Macleod; J F Smyth; W R Miller
Journal:  Br J Cancer       Date:  1996-02       Impact factor: 7.640

2.  NGF/TRKA Decrease miR-145-5p Levels in Epithelial Ovarian Cancer Cells.

Authors:  Maritza P Garrido; Ignacio Torres; Alba Avila; Jonás Chnaiderman; Manuel Valenzuela-Valderrama; José Aramburo; Lorena Oróstica; Eduardo Durán-Jara; Lorena Lobos-Gonzalez; Carmen Romero
Journal:  Int J Mol Sci       Date:  2020-10-16       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.